Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi)

Publication date: August 2019Source: Cytotherapy, Volume 21, Issue 8Author(s): R. Ciccocioppo, D.C. Baumgart, C.C. Dos santos, J. Galipeau, C. Klersy, G. OrlandoAbstractInflammatory bowel disease (IBD), namely, Crohn's disease and ulcerative colitis, remains a grievous and recalcitrant problem incurring significant human and health care costs, even in consideration of the growing incidence. Initial goals of care aimed to achieve the induction and maintenance of clinical remission. The advent of novel treat-to-target approaches using patient stratification, early introduction of immunosuppressants and rapid escalation to biologics or early use of combination therapy has refocused the goals of care toward the achievement of mucosal healing. This is in an attempt to preserve intestinal function, decrease hospitalization and surgery rates and improve the quality of life of affected patients. Cellular therapeutics for the treatment of IBD offers an unprecedented opportunity to change the current paradigm from single-targeted to systems-targeted therapy, trying to dampen the whole inflammatory cascade instead of a only molecule. Therefore, as we move forward, the importance of designing informative and possibly adaptive trial designs, standardizing methodologies, harmonizing goals of therapy and evaluating methods cannot be underemphasized. In this article, we review the current literature on the application of mesenchymal stromal cells for the treatment of IBD in an effort to esta...
Source: Cytotherapy - Category: Cytology Source Type: research

Related Links:

Authors: Mahamid M, Bar-Gil Shitrit A, Amara H, Koslowsky B, Ghantous R, Safadi R Abstract BACKGROUND: Crohn's disease and ulcerative colitis are the two major classic presentations of inflammatory bowel diseases (IBD). Studies have shown a wide variation in the incidence and prevalence attributed to different geographic and ethnic populations. OBJECTIVES: To assess the clinical characteristics of IBD among Arabs in Israel and to compare them to characteristics of IBD among Ashkenazi Jews. METHODS: This retrospective, comparative study compared the clinical characteristics of IBD among 150 Arabs from the Ho...
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
Elective abdominal surgery for inflammatory bowel disease is common. Surgery for Crohn ’s disease is not curative, and treatment must be individualized to the disease process. Surgery for ulcerative colitis generally is curative but consideration of patient-specific factors is important for staging of the procedure and determining whether ileal pouch–anal anastomosis is appropriat e.
Source: Surgical Clinics of North America - Category: Surgery Authors: Source Type: research
CONCLUSION: In this study, we demonstrate that risk factors for NAFLD and LF in the IBD population do not differ from those in the general population. PMID: 31602167 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
ConclusionCombination therapy with 50  mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UC patients seem to benefit and prefer lower doses whereas the contrary is seen in CD patients.Trial registrationEudraCT trial registry - number2016-001638-84
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions: We demonstrate that the risk of relapse in ulcerative colitis can be predicted by consecutively measuring faecal EDN every third month, and suggest EDN as a complementary faecal marker to calprotectin to predict future relapse in ulcerative colitis. Our finding of higher EDN in Crohn's disease-patients staying in remission than in those who relapsed indicates different functions of the protein in ulcerative colitis and Crohn's disease. PMID: 31577465 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Conclusions: Defining the landscape of MNPs in MLNs provided evidence for expansion of CD163+ Mono/MΦ-like cells in UC only, highlighting a distinction between UC and CD, and thus the potential co ntribution of monocyte-like cells in driving colitis.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Although the number of available therapies for the treatment of ulcerative colitis (UC) and Crohn ’s disease (CD) continues to expand, a significant portion of patients with inflammatory bowel disease (IBD) will require surgical intervention. Surgery remains an integral part of the treatment algorithm for patients with UC and CD, and thus multidisciplinary approaches to the perioperative and p ostoperative management of patients with IBD are critical to improving outcomes during these periods. New mechanisms of biologic therapies are emerging and new treatment strategies focused on earlier and potentially more aggres...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Condition:   Ulcerative Colitis Intervention:   Drug: Tauroursoursodeoxycholic acid, brand name Tudcabil Sponsors:   Washington University School of Medicine;   Crohn's and Colitis Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 11 June 2019Source: CytotherapyAuthor(s): R. Ciccocioppo, D.C. Baumgart, C.C. Dos santos, J. Galipeau, C. Klersy, G. OrlandoAbstractInflammatory bowel disease (IBD), namely, Crohn's disease and ulcerative colitis, remains a grievous and recalcitrant problem incurring significant human and health care costs, even in consideration of the growing incidence. Initial goals of care aimed to achieve the induction and maintenance of clinical remission. The advent of novel treat-to-target approaches using patient stratification, early introduction of immunosuppressants and rapid escalation to biol...
Source: Cytotherapy - Category: Cytology Source Type: research
Large study finds key mutations that may be tied to raised risk for inflammatory bowel disease Source: HealthDay Related MedlinePlus Pages: Crohn's Disease, Digestive Diseases, Genes and Gene Therapy
Source: MedlinePlus Health News - Category: Consumer Health News Source Type: news
More News: Clinical Trials | Crohn's Disease | Cytology | Gastroenterology | Gene Therapy | Genetics | Health Management | Inflammatory Bowel Disease | Ulcerative Colitis